Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

Analysis of the Evolution of CAR T-cell Immunotherapy through Patenting Activity

Nature Biotechnology review of emerging technology of chimeric antigen receptor (CAR) T-cell immunotherapy shows six of the top 20 global CAR-T inventors are from Penn.

Penn's Gene Therapy Startup Raises Another $50 Million

Funding for cellular therapies that target specific B cells that mediate a wide variety of autoimmune conditions.

National Blood Foundation Early-Career Grant for Dr. Vijay Bhoj

Award for research in the fields of transfusion medicine and cellular therapies.

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Global CAR T Therapy Trial Shows High Rates of Durable Remission for Non-Hodgkin’s Lymphoma: Additional data shows remissions past two years among patients treated in earlier pilot study.

Cancer Immunotherapy Research

20 years of Penn Medicine's "ImmunoRevolution" that has created personalized immunotherapy treatments to reprogram the immune system to recognize and kill cancer cells.